Gary.boutte1941@gmail.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will buy at .025 if it decides to dive like yesterday. If it continues to climb...I'm good with that too!!
Signal Update: AMERICAN BULLS
Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 12/18/2018, 1 day ago, when the stock price was 0.0164. Since then PPCB has risen by +76.83%.
Looking at that .057 real hard.
It's moving again, pass the .037 mini wall and clear to .045
We just went to Number 4 on Breakout Board.....lots of Ihub eyes will see this.
Wish I could play the stock...I have to wait for the settlement every time I sell and that takes 3 days.
Did that once and it exploded in 2 days and was late to the dance.
Now have to hold.
light the friggin wick!!!
Right on...he just just put it up at .05
walls down now...smooth sailing.
I bought more at .031 this morning to get it moving...it did!!!
Like you mentioned, timing.
Wall at .04 ETRF....new one at .0475 250,000 shares
That would put me at $70 grand with my 250,000 shares on hand.
Hello all-in888
Been there...got the t-shirt!!!
Hope this is reasonable now, need stronger news of setting up trials.
next wall at .047
ASK sitting on .045
open .031
High for week was .057
Maybe we can shoot for that number!!!
Read my post #40836 12/18/18
My crystal ball must have given good information...lol
We may hear something in the order of patents being accepted in some countries and gearing up for the trials.
Someone must be loading for good news down the pike!
Tested .057 earlier!!!!
Wants to open at .04 today!!!
Been here for a few years...seen this before!
You are just about done with some dilution and bingo comes a PR.
Then when people are scratching their heads saying "why", they answer with some breaking news within a few weeks.
I think they want to go out with a bang....and with this new company we may get better service as to putting our name out there.
The other company did absolutely nothing with promoting PPCB.
We may hear something in the order of patents being accepted in some countries and gearing up for the trials.
Sitting on 1/4 million shares [today made over $5000], so, be patient and don't listen to the so called experts. Things get going when the ba$her$ and penny flippers enter the arena.
Looking to see .04 or .05 tomorrow and .10 next week.
Gotta clean that crystal ball again folks...all speculation at this point.
Thought it would climb to .04 today....maybe tomorrow!!
Propanc Biopharma Selects LaVoieHealthScience as Integrated Communications Partner
9:00 am ET December 18, 2018 (BusinessWire) Print
Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that Propanc has selected LaVoieHealthScience ("LHS") as its communications agency of record. LHS is an integrated investor and public relations agency focused on advancing health and science innovations. Propanc is partnering with LHS to develop corporate awareness of Propanc as a health science innovator as it transitions its lead technology into human clinical trials.
Propanc is developing new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent cancer from returning and spreading. Its lead product, PRP, is an enhanced proenzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company's initial target patient populations include pancreatic, ovarian and colorectal cancers. Propanc's treatment for pancreatic cancer received Orphan Drug Designation by the U.S. Food and Drug Administration in 2017. For more information on PRP's Mechanism of Action, view this video at:http://www.propanc.com/news-media/video
"As we move closer to the clinical trials stage, it's critically important to build the right reputation amongst key stakeholders. LHS, with its proven track record in providing integrated communications to global health science innovators, will be a great long-term partner as we continue to drive PRP forward with our drug discovery efforts," said James Nathanielsz, CEO and Executive Chairman of Propanc. "LHS stood out with its deep understanding of our value proposition across targeted channels and audiences, its team of high-touch senior communicators, and proprietary approach to creating targeted messaging mapped to stakeholders as the underpinning of a strategic communications program. We are looking forward to a long and productive relationship."
Donna L. LaVoie, President & CEO of LHS commented, "We are delighted to be working with the Propanc Biopharma team to bring attention to their pioneering work targeting cancer stem cells. We look forward to supporting Propanc Biopharma as it brings novel therapies into the clinical trials stage to provide new hope for patients suffering from metastatic cancer."
5 million shares trading in 1 minute!!!!!
At least it won't tank today...lol
The Phase Ib study is planned to be followed by two open Phase IIa studies evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP administered intravenously to patients with locally advanced or metastatic pancreatic adenocarcinoma, or to patients with advanced epithelial ovarian cancer who have failed prior anti-cancer therapy regimen. These studies are envisioned to start in parallel, shortly after the FIH Phase IIa study, and are hoped to be finalized in 2021. Both studies will be open, multicenter phase II studies measuring overall survival of patients having received once daily intravenous administrations of PRP.
Our Development Strategy
Our goal is to undertake early stage clinical development of PRP through to a significant value inflection point, where the commercial attractiveness of a drug in development, together with a greater likelihood of achieving market authorization, may attract potential interest from licensees seeking to acquire new products. Such value inflection points in the context of cancer drugs are typically at the point where formal, controlled clinical trials have demonstrated either ‘efficacy’ or ‘proof of concept’ – typically meaning that there is controlled clinical trial evidence that the drug is effective in the proposed target patient population, has an acceptable safety profile, and is suitable for further development. From a ‘big picture’ perspective, it is our intention to progress the development of our technology through the completion of our planned Phase IIa clinical trials and then to seek a licensee for further development beyond that point.
As part of that commercial strategy, we will:
? continue research and development to build our existing intellectual property portfolio, and to seek new, patentable discoveries;
? seek to ensure all product development is undertaken in a manner that makes its products approvable in the major pharmaceutical markets, including the U.S., Europe, the UK and Japan;
? aggressively pursue the protection of our technology through all means possible, including patents in all major jurisdictions, and potentially trade secrets; and
? make strategic acquisitions to acquire new companies that have products or services that complement our future goals.
Our Development Plan and Milestones
We plan to progress PRP down a conventional early stage clinical development pathway in the UK for:
? regulatory approval to conduct a Phase Ib study, and submit it to the European Medicines Agency for approval; and
? Phase IIa multiple escalating dose studies to investigate the safety, tolerability, and pharmacokinetics of PRP administered intravenously to patients.
We anticipate reaching the Phase IIa proof of concept milestone in approximately three to four years, subject to regulatory approval in Europe, and the results from our research and development and licensing activities.
Our overhead and expenses are likely to increase from its current level as PRP progresses down the development pathway. This increase will be driven by the need to increase our internal resources in order to effectively manage our research and development activities.
Commencing in the third quarter of calendar year 2019, we intend to initiate a Phase Ib study in advanced cancer patients with solid tumors and the anticipated costs will be approximately $2,500,000. We intend to use the proceeds of the Equity Line to fund our planned Phase I, II and III clinical trials.
Our principal executive office is located at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia. Our telephone number is +61-03-9882-6723 and our website is www.propanc.com. Unless expressly noted, none of the information on our website is part of this prospectus or any prospectus supplement. Our common stock is quoted on the OTCQB Marketplace operated by the OTC Markets Group, Inc., or “OTCQB,” under the ticker symbol “PPCB.”
10/30/18 424B3 Prospectus filed pursuant to Rule 424(b)(3)
We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, over the last year we have conducted successful pre-clinical studies on PRP and subject to us receiving adequate financing, hope to submit a clinical trial application in the United Kingdom (the “UK”) in the first half of the 2019 calendar year. We intend to develop our PRP to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening.
Notice of Effectiveness
What is an SEC "notice of effectiveness"? The notice of effectiveness is a public declaration by the Securities and Exchange Commission that a public company's registration statement has been accepted. For shares in a public company to trade on the open market they must be registered by the company.
Securities Registration Statement (s-1)
PRELIMINARY Prospectus, SUBJECT TO COMPLETION, DATED OCTOBER 17, 2018
As a penny stock and listed as OTCQB: PPCB, they are required to lay it all out to read. I have penny stocks that haven't put any news for years....heard S.E.C. is looking into this practice and will require companies to post within 6 months or be de-listed.
PPCB stays current!!!
.......the two employees [lol]
Guess that is better than "frick and frack".
.085 on the ASK this morning, we may have a great open.
Hey Jersey...as you can see, this board is very quiet!!!
You will see some come out when it climbs and taking full responsibility.
You will see some come out when it tanks and saying, "I warned you".
A fun board if you keep it real.
Been here since early 2014 and have seen the ups and downs.....all I can advise is BE PATIENT.
Board has been quiet, we have a few come on to try and turn things around in a negative fashion!
Still on a buy/hold segment....next resistance should be around .11
Better for stock to go up and down with no drastic move.
PPCB tested .25 a month ago, let it cruise again!!!!
Good Morning ALL, setting up for run...as you described.
Yes, resistance now will be around .11 and the sky is the limit.
Keep it real, some on board are clueless [ME]...lol
Hugh wall at .096
Break that and its smooth sailing to .10
Friday this touched .10 again.......don't be surprised it it hits that right away Monday.
Thanks for the heads up, I know they pay for production of information.
Think some don't see everything that is printed...this is me putting in my two cents. I realize we have no effect for the stock on this board, I don't have technical or chart experience....so, i copy paste a lot...lol
Been here since 2014 and have see a lot, I'm 77 and this is just a hobby playing with OPM [other people's money]
HENDERSON, NV / ACCESSWIRE / October 4, 2018 / Verastem, Inc., a biopharmaceutical company, with two potential therapies for leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. Recently made its investors a boatload signing some major deals. While it may be a little late on VSTM, there is another company working on a solution to the same cancers that has made impressive progress recently and could be the next major success story in the sector, Propanc Biopharma, Inc. (PPCB).
PPCB is an intriguing biotech firm, that erupted for over 7000% last month going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain as of the close on Wednesday. PPCB may start receiving increased attention from the street at any moment. PPCB has a 52 week high of $0.77. PPCB is currently readying for its Phase 1 Clinical Trial of its lead product PRP, which was granted FDA Orphan Drug Designation for Pancreatic cancer. If this is the first time you are hearing about PPCB, start doing your own research now. PPCB is an impressive biotech firm, with a serious patent portfolio. Those that find PPCB before its clinical trial could be in store for a great ride.
PPCB also discovered a key gene target for drug developers, Rac1B, which increased as a result of PRP treatment. This gene suppresses cellular motility and proliferation of CSCs by ultimately inhibiting TGF-ß, a known growth factor responsible for tumorigenesis and metastasis.
PPCB's CEO James Nathanielsz said "We remain excited by these important discoveries, as suppressing the CSCs population whilst avoiding potential unwanted side effects towards normal stem cells means we have a targeted therapy that can control the spread of cancer. Metastasis, or spreading cancer, remains the main cause of patient death from cancer."
The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
The company is also very close to its first-in-human studies. PPCB has some very exciting events on the horizon. Now is the perfect time to beat the crowd on PPCB.
A few companies to watch include: Propanc Biopharma, Inc. (PPCB), Verastem, Inc. (VSTM), New Age Beverages, Corp. (NBEV), Aphiria, Inc. (APHQF), and Oragenics, Inc. (NYSE American: OGEN).
Propanc Biopharma, Inc. (PPCB)
Market Cap: $11.09M Share Price: $0.068
Propanc Biopharma, Inc. (PPCB), recently announced the execution of a research collaboration agreement with the University of Jaén, Spain, for the provision of research services and scientific-technical advice for the Company's POP1 drug discovery program. The goal for the program is to synthesize and develop a backup clinical compound to the Company's lead product candidate, PRP. The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumors.
Verastem, Inc. (VSTM)
Market Cap: $226.24M Share Price: $4.66
Verastem, Inc. (VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, will present at the following upcoming investor conferences:
The Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00pm EDT in New York City, NY, USA.
The Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018 at 8:00am EDT in New York City, NY, USA.
New Age Beverages Corp (NBEV)
Market Cap: $442.11M Share Price: $8.95
New Age Beverages Corp will be meeting with some of the major retailers in the country at NACS and will be taking orders on a first come, first serve basis, given anticipated demand. Zach Ross, Marketing Manager of the Brand Marley at New Age commented, "We believe we have developed unique consumer insights and accessed superior technology in CBD-infused beverages over the past year, and we are excited to share those insights with key retail partners. We believe we are in a position to bring national leadership to this emerging growth segment, and intend to launch the most efficacious and safe CBD-infused products for consumers, with the most responsible marketing and education to a segment that has potential to be transformative to healthy functional beverages."
Aphiria, Inc. (APHQF)
Market Cap: $3.28B Share Price: $13.28
Aphria Inc. just announced they will release their first quarter results for 2019 on October 12, 2018.
Oragenics, Inc. (OGEN)
Market Cap: $18.94M Share Price: $1.60
Oragenics, Inc. (OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM). The company presented at two conferences this week in New York City.